SequelSEC

Allarity Therapeutics, Inc. ALLR

Pharmaceutical Preparations · CIK 0001860657 · Fiscal year ends 1231

Revenue
$320.00K
Fiscal year ended 2025-12-31
Operating income
-$12.60M
Fiscal year ended 2025-12-31
Free cash flow
-$14.83M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$14.73MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.93Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue46.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin-4633.8%11th
R&D / revenue2062.8%82th
Operating margin-3939.1%18th
Net margin-3509.7%20th
SBC / revenue150.6%74th
Current ratio2.13x29th
CapEx / revenue2.5%54th

Allarity Therapeutics, Inc. (ALLR) reported revenue of $320.00K and net income of -$11.23M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Allarity Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Allarity Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$320.00K$0
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$12.60M-$27.24M
Net income-$11.23M-$24.52M
Research & development$6.60M$6.10M
Weighted-average diluted sharesUnavailableUnavailable
Pretax income-$11.23M-$24.90M
Income tax expense$0-$381.00K
Diluted EPSUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailable
General & administrative$6.32M$11.44M
Selling & marketingUnavailableUnavailable

Balance

Allarity Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$14.69M$19.53M
Total assets$18.26M$22.65M
Current assets$17.93M$22.34M
Total liabilities$8.43M$10.84M
Current liabilities$8.43M$10.84M
Total equity incl. NCI$9.83M$11.81M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$4.28M$4.18M

Cash flow

Allarity Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$14.82M-$17.35M
Capital expenditures$8.00K$298.00K
Investing cash flow-$8.00K-$298.00K
Financing cash flow$10.65M$36.79M
Net change in cashUnavailableUnavailable
Stock-based compensation$482.00K$71.00K
Common dividends paidUnavailableUnavailable
Common share repurchases$3.19M$0
Depreciation & amortizationUnavailable$9.00K

Derived

Allarity Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$14.83M-$17.65M
Gross marginUnavailableUnavailable
Operating margin-3939.1%Unavailable
FCF margin-4633.8%Unavailable
SBC / revenue150.6%Unavailable
Current ratio2.13x2.06x
Revenue YoY growthUnavailableUnavailable
Net margin-3509.7%Unavailable
R&D / revenue2062.8%Unavailable
CapEx / revenue2.5%Unavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALLR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.